https://aktiv8.io/news/n1qc50iu/norroy-receives-china-s-clearance-for-phase-iii-study-of-177lu-nym032 2026-09-03 never 0.6 https://aktiv8.io/news/n1nluiuf/leqembi-lecanemab-subcutaneous-formulation-as-an-initiation-treatment-for-early-alzheimer- 2026-09-03 never 0.6 https://aktiv8.io/news/ng1aexd/stat-fda-pilot-offers-generative-ai-medical-devices-a-path-to-patients-before-they-are-aut 2026-09-03 never 0.6 https://aktiv8.io/news/n1m4mq49/sensorion-announces-approval-of-clinical-trial-application-in-france-for-sens-601-its-inve 2026-09-03 never 0.6 https://aktiv8.io/news/ngx7c5q/opinion-stat-a-surprising-bright-spot-at-the-fda-on-regulating-unproven-stem-cells 2026-09-03 never 0.6 https://aktiv8.io/news/n18p6z55/hutchmed-announces-licensing-agreement-with-gsk-for-kras-egfr-antibody-conjugate-cancer-th 2026-09-03 never 0.6 https://aktiv8.io/news/ntp0x4c/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liv 2026-09-02 never 0.6 https://aktiv8.io/news/n1r344ys/norroy-bioscience-initiates-pivotal-phase-iii-clinical-trial-of-177lu-nym032-a-psma-target 2026-09-02 never 0.6 https://aktiv8.io/news/ndxav0c/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-unce 2026-09-02 never 0.6 https://aktiv8.io/news/n1c0mqq2/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway 2026-09-02 never 0.6 https://aktiv8.io/news/nj33oyx/heartvue-ai-and-innolitics-achieve-fda-510-k-clearance-for-heartvue-proton-an-ai-powered-c 2026-09-02 never 0.6 https://aktiv8.io/news/n1x28fj/newron-announces-completion-of-screening-for-enrollment-in-pivotal-phase-3-enigma-trs-1-st 2026-09-02 never 0.6 https://aktiv8.io/news/n5471tu/newbiologix-and-synastra-biotechnology-partner-to-advance-stable-raav-manufacturing-for-du 2026-09-02 never 0.6 https://aktiv8.io/news/n3wtbql/sec-fda-sign-info-sharing-agreement-as-a-signal-to-the-market-on-insider-trading 2026-09-02 never 0.6 https://aktiv8.io/news/n1dguc4y/raziel-therapeutics-and-fosun-pharma-announce-positive-phase-3-results-for-rzl-012-in-subm 2026-09-02 never 0.6 https://aktiv8.io/news/naydczw/treeline-announces-clinical-trial-collaboration-and-supply-agreement-with-roche-to-evaluat 2026-09-02 never 0.6 https://aktiv8.io/news/n16lmlzj/navigating-the-regulatory-labyrinth-how-biotech-leaders-are-rethinking-strategy-in-an-unce 2026-09-02 never 0.6 https://aktiv8.io/news/nwt5z7p/revamped-plan-aims-to-hasten-us-approval-of-treatment-for-als-als-news-today 2026-09-02 never 0.6 https://aktiv8.io/news/nfqwbil/scholar-rock-receives-fda-fast-track-designation-for-apitegromab-facioscapulohumeral-muscu 2026-09-02 never 0.6 https://aktiv8.io/news/nuij2yl/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutical-for-a-fu 2026-09-02 never 0.6 https://aktiv8.io/news/n7ixxty/fda-allows-first-gene-therapy-clinical-trial-for-ultra-rare-pediatric-neurodegenerative-di 2026-09-02 never 0.6 https://aktiv8.io/news/n1g0ig89/united-therapeutics-corporation-announces-fda-acceptance-of-supplemental-new-drug-applicat 2026-09-02 never 0.6 https://aktiv8.io/news/nal4xs5/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-b 2026-09-02 never 0.6 https://aktiv8.io/news/n1fqd3nw/acto-achieves-veeva-gold-product-partner-status-following-a-nearly-decade-long-collaborati 2026-09-02 never 0.6 https://aktiv8.io/news/nhm052z/ono-pharma-enters-into-a-drug-discovery-partnership-with-aitia-in-neurological-diseases 2026-09-02 never 0.6 https://aktiv8.io/news/nop72zh/revolution-medicines-announces-nejm-publication-of-phase-1-2-rasonque-data-supporting-ongo 2026-09-02 never 0.6 https://aktiv8.io/news/n1of4sjw/uniqure-announces-submission-of-biologics-license-application-for-ifezuntirgene-inilparvov 2026-09-02 never 0.6 https://aktiv8.io/news/n1q263zl/norroy-bioscience-initiates-pivotal-phase-iii-clinical-trial-of-177lu-nym032-a-psma-target 2026-09-02 never 0.6 https://aktiv8.io/news/n1t06mxt/novartis-inks-3-2b-subcutaneous-drug-delivery-deal-with-alteogen 2026-09-02 never 0.6 https://aktiv8.io/news/n1djsz7v/bayesian-health-s-fda-cleared-continuous-ai-sepsis-monitor-approved-for-medicare-new-techn 2026-09-02 never 0.6 https://aktiv8.io/news/nmkomn2/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liv 2026-09-02 never 0.6 https://aktiv8.io/news/n1o20mdf/hamamatsu-receives-fda-510-k-clearance-for-nanozoomer-s20md-and-s540md-slide-scanner-syste 2026-09-02 never 0.6 https://aktiv8.io/news/nhbf5b7/fda-allows-first-gene-therapy-clinical-trial-for-ultra-rare-pediatric-neurodegenerative-di 2026-09-02 never 0.6 https://aktiv8.io/news/n1i5nevj/roundup-alteogen-enters-option-license-agreement-with-novartis-newbiologix-synastra-form-b 2026-09-02 never 0.6 https://aktiv8.io/news/nt2wu39/novartis-rhapsido-cuts-ms-progression-in-phase-3-trial-teeing-up-roche-battle-biospace 2026-09-02 never 0.6 https://aktiv8.io/news/n1of6bzp/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines- 2026-09-02 never 0.6 https://aktiv8.io/news/n15uy8tr/acto-achieves-veeva-gold-product-partner-status-following-a-nearly-decade-long-collaborati 2026-09-02 never 0.6 https://aktiv8.io/news/nk4t2a6/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-b 2026-09-02 never 0.6 https://aktiv8.io/news/n146ejvc/ultragenyx-announces-phase-3-aspire-results-in-angelman-syndrome-rare-stock-news 2026-09-02 never 0.6 https://aktiv8.io/news/n97o0r/visionary-receives-phase-2-drill-approval-for-its-pt-leamington-gold-copper-zinc-silver-vm 2026-09-02 never 0.6 https://aktiv8.io/news/n1ac13lr/simcere-inks-license-agreement-with-roche-for-sim0660-the-pharma-letter 2026-09-02 never 0.6 https://aktiv8.io/news/n48glno/scholar-rock-receives-fda-fast-track-designation-for-apitegromab-facioscapulohumeral-muscu 2026-09-02 never 0.6 https://aktiv8.io/news/nsnay2c/teva-announces-positive-topline-results-from-phase-2a-study-in-celiac-disease-for-its-anti 2026-09-02 never 0.6 https://aktiv8.io/news/n3m14v1/biocytogen-enters-into-non-exclusive-licensing-agreement-with-qilu-pharmaceutical-for-a-fu 2026-09-02 never 0.6 https://aktiv8.io/news/n1du3x7g/united-therapeutics-corporation-announces-fda-acceptance-of-supplemental-new-drug-applicat 2026-09-02 never 0.6 https://aktiv8.io/news/n1lcze5n/can-fite-reports-longer-than-anticipated-overall-survival-in-ongoing-pivotal-phase-iii-liv 2026-09-02 never 0.6 https://aktiv8.io/news/n1bfahgs/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asth 2026-09-01 never 0.6 https://aktiv8.io/news/n1qfqo9/atyr-pharma-provides-update-on-timing-of-regulatory-response-for-planned-phase-3-study-of- 2026-09-01 never 0.6 https://aktiv8.io/news/n1av2e0w/alumis-crushed-by-midstage-lupus-flop-but-plots-path-to-phase-3-for-tyk2-inhibitor 2026-09-01 never 0.6 https://aktiv8.io/news/n1m1ne0i/ono-pharma-and-aitia-announce-collaboration-to-identify-novel-drug-targets-in-neurological 2026-09-01 never 0.6 https://aktiv8.io/news/n10zyo5p/ripple-and-settlemint-partner-to-provide-digital-asset-custody-and-tokenization-for-financ 2026-09-01 never 0.6 https://aktiv8.io/news/n1rsxa6q/esc-2026-abbott-presents-positive-longer-term-dual-ablation-catheter-data 2026-09-01 never 0.6 https://aktiv8.io/news/n1vbas3a/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asth 2026-09-01 never 0.6 https://aktiv8.io/news/nae5qsx/xentria-advances-xtmab-16-clinical-development-in-pulmonary-sarcoidosis-following-fda-feed 2026-09-01 never 0.6 https://aktiv8.io/news/n1f0jv4v/medibyt-receives-fda-510-k-clearance-for-cpetwise-advancing-cardiopulmonary-exercise-test- 2026-09-01 never 0.6 https://aktiv8.io/news/n13wgm9g/jazz-reports-phase-iii-trial-interim-results-for-ziihera-combination 2026-09-01 never 0.6 https://aktiv8.io/news/n1jhso35/stat-fda-clears-stryker-s-surgical-cockpit-that-uses-apple-s-vr-headset-vision-pro 2026-09-01 never 0.6 https://aktiv8.io/news/ntus0j1/what-does-biontech-bntx-fda-approval-mean-for-its-2026-covid-vaccine-simplywall-st 2026-09-01 never 0.6 https://aktiv8.io/news/n7g86gi/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway-tlx-stoc 2026-09-01 never 0.6 https://aktiv8.io/news/n18bk9cc/atyr-pharma-provides-update-on-timing-of-regulatory-response-for-planned-phase-3-study-of- 2026-09-01 never 0.6 https://aktiv8.io/news/njy8fdp/alumis-announces-topline-results-from-envudeucitinib-phase-2b-trial-in-systemic-lupus-eryt 2026-09-01 never 0.6 https://aktiv8.io/news/n53iys9/blossomhill-therapeutics-to-present-updated-data-from-ongoing-phase-1-2-solara-trial-of-it 2026-09-01 never 0.6 https://aktiv8.io/news/nmgd68w/parsol-shield-approved-by-fda-dsm-firmenich-setting-a-new-era-for-u-s-sun-protection 2026-09-01 never 0.6 https://aktiv8.io/news/n1fjlmm7/stryker-introduces-first-of-its-kind-fda-authorized-surgical-application-for-apple-vision- 2026-09-01 never 0.6 https://aktiv8.io/news/n1djnjug/xentria-advances-xtmab-16-clinical-development-in-pulmonary-sarcoidosis-following-fda-feed 2026-09-01 never 0.6 https://aktiv8.io/news/n8xgqmf/pyrotech-therapeutics-doses-first-subject-in-phase-1-study-of-ptt-121-the-world-s-first-se 2026-09-01 never 0.6 https://aktiv8.io/news/n16m5hou/medibyt-receives-fda-510-k-clearance-for-cpetwise-advancing-cardiopulmonary-exercise-test- 2026-09-01 never 0.6 https://aktiv8.io/news/n1a464rb/thx-pharma-bbdf-and-biocodex-announce-regulatory-submissions-for-the-phase-3-clinical-tria 2026-09-01 never 0.6 https://aktiv8.io/news/n1i0o10d/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-modifier-ge 2026-09-01 never 0.6 https://aktiv8.io/news/nbgdieg/ocugen-doses-first-patient-in-ocu410-phase-3-trial-ocgn-stock-news-stock-titan 2026-09-01 never 0.6 https://aktiv8.io/news/nqdwa94/lilly-looks-beyond-obesity-with-up-to-2-9b-acquisition-of-merida-biosciences 2026-09-01 never 0.6 https://aktiv8.io/news/n1a8iq1c/weave-bio-announces-collaboration-with-takeda-to-deploy-ai-native-regulatory-automation-ac 2026-09-01 never 0.6 https://aktiv8.io/news/nwaoko7/eit-pharma-raises-35-million-as-hepatitis-d-candidate-sits-with-fda-the-pharma-letter 2026-09-01 never 0.6 https://aktiv8.io/news/n5xxlir/hiro-and-differentia-biotech-collaborate-on-clinical-trial-simulation-clinical-trials-aren 2026-09-01 never 0.6 https://aktiv8.io/news/n1l41fr/styx-biotechnologies-announces-strategic-agreement-with-zoencure-therapeutics-to-accelerat 2026-09-01 never 0.6 https://aktiv8.io/news/nwj7ldf/pmv-pharma-raises-usd-50-8m-to-fund-rezatapopt-nda-submission-in-q1-2027-allsci 2026-09-01 never 0.6 https://aktiv8.io/news/n1s57y9w/payward-and-london-stock-exchange-to-partner-to-accelerate-uk-equity-markets-through-token 2026-09-01 never 0.6 https://aktiv8.io/news/ncjh7pr/ocugen-doses-first-patient-in-global-phase-3-armada3-trial-of-ocu410-for-geographic-atroph 2026-09-01 never 0.6 https://aktiv8.io/news/n1uo61u6/lilly-adds-another-m-a-deal-now-to-acquire-merida-biosciences-the-pharma-letter 2026-09-01 never 0.6 https://aktiv8.io/news/n1nz4u2b/applied-biologics-activates-first-clinical-site-in-phase-3-bioxheal-trial 2026-09-01 never 0.6 https://aktiv8.io/news/n1wre68v/dnak-therapeutics-gatc-health-forge-a-partnership-to-evaluate-accelerate-prioritize-cancer 2026-09-01 never 0.6 https://aktiv8.io/news/n63izxv/intelligent-bio-solutions-achieves-above-98-accuracy-in-method-comparison-study-supporting 2026-09-01 never 0.6 https://aktiv8.io/news/n10xy7fs/cipla-shares-gain-after-it-inks-cancer-treatment-drug-licensing-deal-with-sino-biopharma-a 2026-09-01 never 0.6 https://aktiv8.io/news/nqr5rx9/cipla-signs-exclusive-licensing-agreement-with-sbp-group-for-cancer-drug-tqb2102-sahi 2026-09-01 never 0.6 https://aktiv8.io/news/njqvqcw/ascendis-pharma-asnd-clears-yuviwel-patent-fight-with-global-licensing-deal-simplywall-st 2026-09-01 never 0.6 https://aktiv8.io/news/n18rqgvw/eit-pharma-raises-35-million-as-hepatitis-d-candidate-sits-with-fda-the-pharma-letter 2026-09-01 never 0.6 https://aktiv8.io/news/n1xi2lh5/astrazeneca-completes-license-agreement-with-dizal-for-lung-cancer-treatment-zegfrovy-cont 2026-09-01 never 0.6 https://aktiv8.io/news/n148g11w/battelle-researchers-demonstrate-biotech-breakthrough-for-rare-earth-element-separation 2026-09-01 never 0.6 https://aktiv8.io/news/n1qzqfne/orca-bio-to-present-clinical-data-on-tregzi-and-its-clinical-pipeline-at-the-14 2026-09-01 never 0.6 https://aktiv8.io/news/n4j753h/applied-biologics-activates-first-clinical-site-in-phase-3-bioxheal-trial-globenewswire-co 2026-09-01 never 0.6 https://aktiv8.io/news/nu5n660/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asth 2026-09-01 never 0.6 https://aktiv8.io/news/nvtz2vx/ocugen-announces-first-patient-dosed-in-phase-3-globenewswire-com 2026-09-01 never 0.6 https://aktiv8.io/news/nm5vpk5/thx-pharma-bbdf-and-biocodex-announce-regulatory-submissions-for-the-phase-3-clinical-tria 2026-09-01 never 0.6 https://aktiv8.io/news/n1hthd3o/ideaya-biosciences-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-on-pha 2026-08-31 never 0.6 https://aktiv8.io/news/n1rw20lp/karmanos-now-offers-fda-approved-daraxonrasib-rasonque-for-metastatic-pancreatic-cancer 2026-08-31 never 0.6 https://aktiv8.io/news/n16gerp1/positive-phase-3-survival-results-in-her2-advanced-gea-jazz-pharmaceuticals-oncodaily 2026-08-31 never 0.6 https://aktiv8.io/news/n7l0aqn/ultra-violette-becomes-first-brand-in-the-us-to-launch-a-sunscreen-containing-newly-fda-ap 2026-08-31 never 0.6 https://aktiv8.io/news/n1ys4x87/karyopharm-seeks-fda-review-for-xpovio-myelofibrosis-use-grafa-com 2026-08-31 never 0.6 https://aktiv8.io/news/n91sojd/pmv-pharmaceuticals-announces-updated-promising-rezatapopt-monotherapy-interim-ovarian-can 2026-08-31 never 0.6 https://aktiv8.io/news/n17c89ee/stryker-and-iage-partner-to-advance-clinical-excellence-in-fluorescence-guided-surgery-in- 2026-08-31 never 0.6 https://aktiv8.io/news/n12hy06g/lilly-adds-to-immune-drug-pipeline-with-2-9b-merida-buyout 2026-08-31 never 0.6 https://aktiv8.io/news/nyjs558/ovarian-cancer-trial-reports-a-46-response-rate-fda-filing-planned-stock-titan 2026-08-31 never 0.6 https://aktiv8.io/news/n5y1f69/fda-agrees-to-a-placebo-trial-for-a-drug-aimed-at-a-blood-reaction-affecting-50-000-yearly 2026-08-31 never 0.6 https://aktiv8.io/news/nnijqab/fda-approves-gilead-s-new-single-tablet-hiv-regimen-benzinga-com 2026-08-31 never 0.6 https://aktiv8.io/news/nohesac/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/nz0040o/change-agents-completes-phase-2-of-its-catch-up-agentic-ai-video-studio-platform-developme 2026-08-31 never 0.6 https://aktiv8.io/news/nfu486y/ideaya-biosciences-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-on-pha 2026-08-31 never 0.6 https://aktiv8.io/news/nbmuusp/beone-medicines-announces-new-phase-3-survival-data-reinforcing-benefit-of-ziihera-contain 2026-08-31 never 0.6 https://aktiv8.io/news/n1nczf8f/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-ex 2026-08-31 never 0.6 https://aktiv8.io/news/n1eeqa69/hiro-and-differentia-biotech-collaborate-on-clinical-trial-simulation 2026-08-31 never 0.6 https://aktiv8.io/news/n1l3j2rx/takeda-protagonist-score-broad-fda-nod-in-rare-blood-cancer-setting-up-2b-opportunity 2026-08-31 never 0.6 https://aktiv8.io/news/n177lj85/ideaya-biosciences-announces-successful-fda-type-c-meeting-for-ide849-dll3-top1-adc-on-pha 2026-08-31 never 0.6 https://aktiv8.io/news/nfianqf/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/n1bg45yl/karmanos-now-offers-fda-approved-daraxonrasib-rasonque-for-metastatic-pancreatic-cancer 2026-08-31 never 0.6 https://aktiv8.io/news/ndbs0mv/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/nv17aem/veloxis-pharmaceuticals-doses-first-patient-in-rengevity-201-phase-2-trial-of-pegrizeprume 2026-08-31 never 0.6 https://aktiv8.io/news/n1o4y20h/eit-pharma-closes-oversubscribed-35-million-series-a-round-led-by-propel-bio-partners 2026-08-31 never 0.6 https://aktiv8.io/news/n1a9627k/biomarin-and-ascendis-pharma-finalize-patent-settlement-with-royalty-license-agreement-kal 2026-08-31 never 0.6 https://aktiv8.io/news/n1hb7rxl/fda-oks-takeda-protagonist-drug-for-rare-blood-cancer 2026-08-31 never 0.6 https://aktiv8.io/news/n1r70qrw/electra-aims-to-light-up-nasdaq-with-ipo-for-phase-2-3-i-i-push 2026-08-31 never 0.6 https://aktiv8.io/news/n801t35/beone-s-cancer-regimen-gets-fda-approval-after-median-survival-exceeded-two-years-stock-ti 2026-08-31 never 0.6 https://aktiv8.io/news/n1kzffc1/beone-medicines-announces-new-phase-3-survival-data-reinforcing-benefit-of-ziihera-contain 2026-08-31 never 0.6 https://aktiv8.io/news/ne819fu/eli-lilly-inks-2-88b-merida-buyout-for-autoimmune-drugs-against-rogue-antibodies 2026-08-31 never 0.6 https://aktiv8.io/news/n16q68nf/vertex-pharma-stock-trades-above-540-as-crinetics-merger-clears-key-hurdle-ad-hoc-news 2026-08-31 never 0.6 https://aktiv8.io/news/nsietoz/cadrenal-therapeutics-announces-fda-alignment-on-phase-3-primary-endpoint-for-cad-1005-hit 2026-08-31 never 0.6 https://aktiv8.io/news/n1u3zn3v/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-ex 2026-08-31 never 0.6 https://aktiv8.io/news/ndsz77h/alvotech-announces-fda-acceptance-for-review-of-biologics-license-application-for-avt80-ex 2026-08-31 never 0.6 https://aktiv8.io/news/n11pmf7q/cadrenal-therapeutics-announces-positive-outcome-from-fda-globenewswire-com 2026-08-31 never 0.6 https://aktiv8.io/news/n92we55/eit-pharma-closes-oversubscribed-35-million-series-a-round-led-by-propel-bio-partners 2026-08-31 never 0.6 https://aktiv8.io/news/n1bsazz7/kennedy-wilson-and-shimizu-corporation-partner-on-382-unit-multifamily-development-in-sand 2026-08-31 never 0.6 https://aktiv8.io/news/n1t9db47/endovia-health-sciences-welcomes-historic-shift-in-federal-cannabinoid-policy-advances-can 2026-08-31 never 0.6 https://aktiv8.io/news/n1qy4hbg/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-meeting-for-phase-3-regis 2026-08-31 never 0.6 https://aktiv8.io/news/n1uibeg/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus- 2026-08-31 never 0.6 https://aktiv8.io/news/nfyhx11/palvella-therapeutics-completes-rolling-submission-of-new-drug-application-to-fda-for-qtor 2026-08-31 never 0.6 https://aktiv8.io/news/nc4225j/axsome-therapeutics-initiates-summit-phase-3-trial-of-axs-05-in-smoking-cessation-axsm-sto 2026-08-31 never 0.6 https://aktiv8.io/news/n1dp5vgv/stat-we-re-reading-about-drug-pricing-deals-a-new-cancer-therapy-approval-and-more 2026-08-31 never 0.6 https://aktiv8.io/news/nny74pc/arrowhead-pharmaceuticals-presents-phase-3-shasta-3-and-shasta-4-data-demonstrating-plozas 2026-08-30 never 0.6 https://aktiv8.io/news/np3mpwt/stockwatch-revolution-shares-stay-flat-despite-historic-fda-approval-of-oral-pancreatic-ca 2026-08-30 never 0.6 https://aktiv8.io/news/n1bgbwb7/arrowhead-pharmaceuticals-presents-phase-3-shasta-3-and-shasta-4-data-demonstrating-plozas 2026-08-30 never 0.6 https://aktiv8.io/news/nm8k1fl/tenax-finds-benefit-in-sicker-patient-subgroup-after-phase-3-trial-miss-tenx-nasdaq 2026-08-30 never 0.6 https://aktiv8.io/news/n1doyefa/fda-approves-protagonist-and-takeda-s-drug-for-rare-blood-cancer 2026-08-30 never 0.6 https://aktiv8.io/news/n1j0kuub/stat-fda-approves-protagonist-and-takeda-s-drug-for-rare-blood-cancer 2026-08-30 never 0.6 https://aktiv8.io/news/n40cdss/tenax-therapeutics-tenx-reports-promising-phase-3-trial-data-a-gurufocus 2026-08-30 never 0.6 https://aktiv8.io/news/n6v0404/tenax-therapeutics-announces-presentation-of-phase-3-level-results-in-late-breaking-scient 2026-08-29 never 0.6 https://aktiv8.io/news/n81azkg/tenax-presents-additional-phase-3-trial-data-for-tnx-103-investing-com 2026-08-29 never 0.6 https://aktiv8.io/news/nj54f6t/tenax-therapeutics-presents-additional-phase-3-level-data-showing-tnx-103-benefits-in-ph-h 2026-08-29 never 0.6 https://aktiv8.io/news/n10vltbc/askbio-presents-baseline-characteristics-from-phase-2-heart-failure-gene-therapy-trial-of- 2026-08-29 never 0.6 https://aktiv8.io/news/n1lp6m2z/women-leaders-association-adds-lisa-reilly-as-boston-coaching-partner-bringing-23-years-of 2026-08-29 never 0.6 https://aktiv8.io/news/n18mm5jj/tenax-therapeutics-announces-presentation-of-phase-3-level-globenewswire-com 2026-08-29 never 0.6 https://aktiv8.io/news/n2twk7r/cipla-pharma-license-cancellation-fda-withdraws-order-after-hc-raps-it-for-going-overboard 2026-08-29 never 0.6 https://aktiv8.io/news/n1ndl3fi/tenax-therapeutics-announces-presentation-of-phase-3-level-results-in-late-breaking-scient 2026-08-29 never 0.6 https://aktiv8.io/news/nd21zeh/tenax-therapeutics-announces-presentation-of-phase-3-level-results-in-late-breaking-scient 2026-08-29 never 0.6 https://aktiv8.io/news/nbwylg8/a-post-hoc-phase-3-subgroup-analysis-found-tenax-s-drug-cut-a-heart-stress-marker-47-versu 2026-08-29 never 0.6 https://aktiv8.io/news/nlbymm9/hagens-berman-alerts-capricor-therapeutics-inc-nasdaq-capr-investors-to-fda-review-extensi 2026-08-28 never 0.6 https://aktiv8.io/news/nntn6xi/stat-cytokinetics-details-trial-win-for-what-could-be-its-next-approval 2026-08-28 never 0.6 https://aktiv8.io/news/n1iqq177/durham-biotech-scores-fda-approval-for-potential-blockbuster-drug-the-business-journals 2026-08-28 never 0.6 https://aktiv8.io/news/n1lp78hi/fda-approves-gilead-s-new-once-daily-hiv-pill-bixlenvo-labroots 2026-08-28 never 0.6 https://aktiv8.io/news/nmydf1j/zambon-announces-european-commission-approval-of-hopledo-for-adults-with-parkinson-s-disea 2026-08-28 never 0.6 https://aktiv8.io/news/n1cvdxto/innolitics-and-beacon-neuro-ai-partner-to-bring-fda-breakthrough-device-beaconpredict-to-m 2026-08-28 never 0.6 https://aktiv8.io/news/nne9rvz/ausperbio-adds-120m-series-c-to-advance-hep-b-oligo-therapy-through-phase-3-and-beyond 2026-08-28 never 0.6 https://aktiv8.io/news/n1e97vdv/takeda-receives-u-s-fda-approval-of-mimrylo-rusfertide-marking-a-potential-shift-in-the-tr 2026-08-28 never 0.6 https://aktiv8.io/news/nz453fj/natera-and-susan-g-komen-announce-national-partnership-to-accelerate-progress-against-brea 2026-08-28 never 0.6 https://aktiv8.io/news/n16vesur/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/nuwov85/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/nbsqvi8/byheart-update-fda-confirms-review-of-byheart-s-root-cause-investigation-and-action-plan-f 2026-08-28 never 0.6 https://aktiv8.io/news/n1gyjyx5/moderna-raises-2-6b-to-support-cancer-work-fda-clears-updated-covid-vaccines 2026-08-28 never 0.6 https://aktiv8.io/news/n17bqddd/gc-biopharma-partners-with-france-s-osivax-to-develop-next-gen-flu-shot-chosunbiz-chosunbi 2026-08-28 never 0.6 https://aktiv8.io/news/n1ox8lkz/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/n6kp5el/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/n1vghpkq/create-medicines-expands-clinical-in-vivo-car-pipeline-and-lnp-technology-suite-by-forming 2026-08-28 never 0.6 https://aktiv8.io/news/n18oxjtp/leo-cancer-care-announces-commercial-collaboration-with-leading-healthcare-solutions-provi 2026-08-28 never 0.6 https://aktiv8.io/news/n2q4o8b/fda-approves-lilly-s-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-typ 2026-08-28 never 0.6 https://aktiv8.io/news/n3nfoac/quoin-pharmaceuticals-reports-positive-interim-data-from-ongoing-phase-2-3-study-of-qrx003 2026-08-28 never 0.6 https://aktiv8.io/news/n1alqmof/cytokinetics-announces-positive-phase-3-acacia-hcm-results-for-aficamten-in-non-obstructiv 2026-08-28 never 0.6 https://aktiv8.io/news/nlhrvta/hiro-and-differentia-biotech-forge-strategic-alliance-to-redefine-clinical-trial-design-th 2026-08-28 never 0.6 https://aktiv8.io/news/n1xy7w5/ausperbio-adds-120m-series-c-to-advance-hep-b-oligo-therapy-through-phase-3-and-beyond 2026-08-28 never 0.6 https://aktiv8.io/news/n192bvhc/genentech-strikes-second-asia-deal-in-a-week-betting-up-to-1b-in-oncology-adc-alliance-wit 2026-08-28 never 0.6 https://aktiv8.io/news/n2eckq7/lilly-joins-novo-in-cardiovascular-space-after-fda-nod-for-glp-1-gip-agonist-mounjaro 2026-08-28 never 0.6 https://aktiv8.io/news/ndpm2tz/novo-nordisk-dominates-oral-obesity-drug-market-pressuring-eli-lilly-with-phase-3-trial-of 2026-08-28 never 0.6 https://aktiv8.io/news/nagmrcn/mbx-biosciences-doses-first-patient-in-phase-3-canvuparatide-trial-for-hypoparathyroidism- 2026-08-28 never 0.6 https://aktiv8.io/news/nhyv4v1/pfizer-and-biontech-win-fda-approval-for-xfg-adapted-covid-vaccine-the-pharma-letter 2026-08-28 never 0.6 https://aktiv8.io/news/nwf6ura/kowa-pharmaceuticals-america-announces-fda-acceptance-of-new-drug-application-for-k-911-an 2026-08-27 never 0.6 https://aktiv8.io/news/ngblzwo/l-innovation-collaborative-propulse-precision-biologic-sur-le-devant-de-la-scene-en-diagno 2026-08-27 never 0.6 https://aktiv8.io/news/n1c77d57/innovation-through-collaboration-puts-precision-biologic-on-the-map-in-hemostasis-diagnost 2026-08-27 never 0.6 https://aktiv8.io/news/nfytpz0/abbvie-submits-regulatory-application-to-ema-for-skyrizi-risankizumab-subcutaneous-inducti 2026-08-27 never 0.6 https://aktiv8.io/news/n1bv75jj/adicet-bio-announces-fda-clearance-of-ind-application-for-adi-212-acet-stock-news 2026-08-27 never 0.6 https://aktiv8.io/news/n121m738/bausch-lomb-dry-eye-combo-drop-advances-to-phase-3-evaluation-glance-by-eyes-on-eyecare 2026-08-27 never 0.6 https://aktiv8.io/news/nk9e411/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co- 2026-08-27 never 0.6 https://aktiv8.io/news/n1tt4bi1/tezepelumab-meets-coprimary-endpoints-in-phase-3-eoe-trial-medical-professionals-reference 2026-08-27 never 0.6 https://aktiv8.io/news/n1tcuh65/tezspire-hits-both-primary-endpoints-in-phase-3-eosinophilic-esophagitis-trial-the-clinica 2026-08-27 never 0.6 https://aktiv8.io/news/n1gnzpdi/nicox-announces-april-2027-pdufa-date-for-ncx-470-in-glaucoma 2026-08-27 never 0.6 https://aktiv8.io/news/n17s7lig/fda-inspection-data-reveals-a-new-compliance-blind-spot-for-medical-device-makers 2026-08-27 never 0.6 https://aktiv8.io/news/noy1x2y/amgen-az-s-tezspire-lands-phase-3-eosinophilic-esophagitis-win-turning-up-heat-on-dupixent 2026-08-27 never 0.6 https://aktiv8.io/news/n1tp1tyz/nicox-announces-april-2027-pdufa-date-for-ncx-470-in-glaucoma-the-manila-times 2026-08-27 never 0.6 https://aktiv8.io/news/n3z6yu5/verrica-completes-enrollment-in-phase-3-ycanth-common-warts-trial-dermatology-times 2026-08-27 never 0.6 https://aktiv8.io/news/n1buvcvh/mission-therapeutics-and-neuralight-partner-to-bring-precision-brain-function-biomarkers-t 2026-08-27 never 0.6 https://aktiv8.io/news/n1e2mn63/u-s-fda-approves-revolution-medicines-rasonque-daraxonrasib-the-first-broad-ras-targeted-m 2026-08-27 never 0.6 https://aktiv8.io/news/n1cedxms/viva-biotech-announces-its-2026-interim-results-ai-sparks-new-paradigm-in-drug-r-d-cdmo-co 2026-08-27 never 0.6 https://aktiv8.io/news/nks4648/rockpoint-and-holland-partner-group-announce-joint-venture-to-develop-stevens-creek-in-san 2026-08-27 never 0.6 https://aktiv8.io/news/npjtud6/china-s-akeso-says-cancer-drug-beat-astrazeneca-s-imfinzi-in-phase-3-trial-south-china-mor 2026-08-27 never 0.6 https://aktiv8.io/news/ngvqttq/stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump-deal-with- 2026-08-27 never 0.6 https://aktiv8.io/news/nydw193/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-pivotal-phase-3-trial- 2026-08-27 never 0.6 https://aktiv8.io/news/n1f303l0/pfizer-and-biontech-receive-u-s-fda-approval-for-xfg-adapted-covid-19-vaccine 2026-08-27 never 0.6 https://aktiv8.io/news/n1k7h2zc/sl-science-highlights-new-fda-drug-master-file-for-gdt-cell-derived-exosomes-expanding-the 2026-08-27 never 0.6 https://aktiv8.io/news/n1fx45fn/mbx-biosciences-announces-first-patient-dosed-in-pivotal-phase-3-optimize-trial-of-once-we 2026-08-27 never 0.6 https://aktiv8.io/news/naf46i5/amgen-tezspire-phase-3-trial-shows-eoe-improvements-grafa-com 2026-08-27 never 0.6 https://aktiv8.io/news/n48qcpr/letsgetchecked-powered-by-fuze-health-partners-with-waters-corporation-to-bring-the-most-c 2026-08-27 never 0.6 https://aktiv8.io/news/n6zuxbd/eascra-biotech-awarded-7-96-million-nasa-inspa-phase-2-contract-to-advance-space-manufactu 2026-08-27 never 0.6 https://aktiv8.io/news/n1v8pmwv/adicet-bio-announces-fda-clearance-of-ind-application-for-adi-212 2026-08-27 never 0.6 https://aktiv8.io/news/necfi5a/pfizer-and-biontech-receive-u-s-fda-approval-for-xfg-adapted-covid-19-vaccine 2026-08-27 never 0.6 https://aktiv8.io/news/nd7907u/osivax-and-gc-biopharma-enter-strategic-collaboration-to-develop-a-next-generation-influen 2026-08-27 never 0.6 https://aktiv8.io/news/n120hnbv/biohaven-sk-biopharma-sign-kv7-licensing-deal-voice-of-healthcare 2026-08-27 never 0.6 https://aktiv8.io/news/n19aon0l/abbvie-submits-regulatory-application-to-ema-for-skyrizi-risankizumab-subcutaneous-inducti 2026-08-27 never 0.6 https://aktiv8.io/news/n11j83w9/agenus-announces-updated-nest-phase-2-publication-reporting-deep-pathologic-responses-and- 2026-08-27 never 0.6 https://aktiv8.io/news/nf3qz8h/stat-fda-approves-roivant-therapy-for-rare-autoimmune-disease 2026-08-27 never 0.6 https://aktiv8.io/news/n1ne225d/solstice-advanced-materials-announces-mutual-termination-of-merger-agreement-with-element- 2026-08-27 never 0.6 https://aktiv8.io/news/n963zqb/rongtao-medical-publishes-legacy-ultrasound-cybersecurity-framework-built-on-fda-cisa-and- 2026-08-27 never 0.6 https://aktiv8.io/news/n388asr/uniphore-and-tech-mahindra-partner-to-deliver-an-agentic-ai-factory-for-the-enterprise 2026-08-27 never 0.6 https://aktiv8.io/news/n9rys22/redx-closes-of-36-million-series-a-financing-ahead-of-skye-merger-the-pharma-letter 2026-08-27 never 0.6 https://aktiv8.io/news/n1o63io2/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co- 2026-08-27 never 0.6 https://aktiv8.io/news/n7eoj8f/stat-cassidy-criticizes-fda-oversight-of-abortion-pill-manufacturers-in-new-report 2026-08-27 never 0.6 https://aktiv8.io/news/n613t7/corvus-pharmaceuticals-announces-publication-in-blood-of-final-phase-1-data-from-the-soque 2026-08-27 never 0.6 https://aktiv8.io/news/n2o254/kenorland-minerals-and-targa-exploration-commence-phase-2-drill-program-at-the-opinaca-pro 2026-08-27 never 0.6 https://aktiv8.io/news/n1secjb3/mbx-biosciences-announces-first-patient-dosed-in-pivotal-phase-3-optimize-trial-of-once-we 2026-08-27 never 0.6 https://aktiv8.io/news/nlho2lg/psilera-appoints-neuroscience-veteran-allyson-gage-phd-as-vice-president-clinical-developm 2026-08-27 never 0.6 https://aktiv8.io/news/n19snhx9/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-pivotal-phase-3-trial- 2026-08-27 never 0.6 https://aktiv8.io/news/n1qvldzv/fibrobiologics-releases-third-batch-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ul 2026-08-27 never 0.6 https://aktiv8.io/news/n1wslwcg/u-s-fda-approves-gilead-s-bixlenvo-a-new-once-daily-single-tablet-option-for-virologically 2026-08-27 never 0.6 https://aktiv8.io/news/n1k3xgyv/roche-nabs-expanded-fda-approval-for-diagnostic-tied-to-jazz-s-cancer-drug 2026-08-27 never 0.6 https://aktiv8.io/news/n15lj2ot/cytomx-therapeutics-announces-fda-fast-track-designation-for-varsetatug-masetecan-varseta- 2026-08-27 never 0.6 https://aktiv8.io/news/n15xlxrt/fibrobiologics-releases-third-batch-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ul 2026-08-27 never 0.6 https://aktiv8.io/news/n4l62mc/kowa-pharmaceuticals-america-announces-fda-acceptance-of-new-drug-application-for-k-911-an 2026-08-27 never 0.6 https://aktiv8.io/news/n1s0ywx0/akeso-2026-interim-results-strong-commercialization-momentum-io2-0-global-strategy-redefin 2026-08-27 never 0.6 https://aktiv8.io/news/n1ui72v7/innovation-through-collaboration-puts-precision-biologic-on-the-map-in-hemostasis-diagnost 2026-08-27 never 0.6 https://aktiv8.io/news/n17y8o5/fibrobiologics-releases-third-batch-of-cywc628-drug-product-for-phase-1-2-diabetic-foot-ul 2026-08-27 never 0.6 https://aktiv8.io/news/n17oqe4w/psilera-appoints-neuroscience-veteran-allyson-gage-phd-as-vice-president-clinical-developm 2026-08-27 never 0.6 https://aktiv8.io/news/n1rcd4py/piramal-pharma-renforce-ses-operations-pretes-pour-l-avenir-avec-une-reduction-de-22-6-des 2026-08-27 never 0.6 https://aktiv8.io/news/ndf13qn/tezspire-demonstrates-positive-phase-3-results-in-eosinophilic-esophagitis-across-both-co- 2026-08-27 never 0.6 https://aktiv8.io/news/n14xc48k/a-phase-3-epilepsy-study-is-among-xenon-s-six-planned-europe-presentations-stock-titan 2026-08-26 never 0.6 https://aktiv8.io/news/noq6j3i/monod-bio-licenses-ai-designed-protein-technologies-to-signalchem-biotech-for-custom-disco 2026-08-26 never 0.6 https://aktiv8.io/news/n3n5fsf/vivace-therapeutics-strengthens-leadership-team-as-it-prepares-to-advance-vt3989-the-first 2026-08-26 never 0.6 https://aktiv8.io/news/n144a6pv/vivace-therapeutics-strengthens-leadership-team-as-it-prepares-to-advance-vt3989-the-first 2026-08-26 never 0.6 https://aktiv8.io/news/n1fqesbc/sk-biopharmaceuticals-to-in-license-epilepsy-drug-candidate-opakalim 2026-08-26 never 0.6 https://aktiv8.io/news/n1alsds5/fda-grants-fast-track-designation-to-sotio-s-sot106-adc-for-soft-tissue-sarcoma-treatment- 2026-08-26 never 0.6 https://aktiv8.io/news/np47pp2/precisionlife-selects-gencove-as-us-partner-to-launch-and-deliver-dna-wellness-reports 2026-08-26 never 0.6 https://aktiv8.io/news/n151lfb9/fda-greenlights-revolution-medicines-pancreatic-cancer-gamechanger-fierce-pharma 2026-08-26 never 0.6 https://aktiv8.io/news/n1d388tx/u-s-fda-approves-viiv-healthcare-s-tivicay-pd-helping-close-a-critical-hiv-treatment-gap-f 2026-08-26 never 0.6 https://aktiv8.io/news/n17swumm/revir-therapeutics-receives-fda-rare-pediatric-disease-designation-for-rtx-117-in-charcot- 2026-08-26 never 0.6 https://aktiv8.io/news/n1f7hm5n/cronus-pharma-launches-first-fda-approved-bioequivalent-robenacoxib-injection-for-veterina 2026-08-26 never 0.6 https://aktiv8.io/news/nouu3k6/fda-approves-daraxonrasib-for-pancreatic-cancer-what-patients-need-to-know-memorial-sloan- 2026-08-26 never 0.6 https://aktiv8.io/news/n117wa4v/viva-biotech-announces-its-2026-interim-results-ai-sparks-new-paradigm-in-drug-r-d-cdmo-co 2026-08-26 never 0.6 https://aktiv8.io/news/n1gfwsyv/viva-biotech-announces-its-2026-interim-results-ai-sparks-new-paradigm-in-drug-r-d-cdmo-co 2026-08-26 never 0.6 https://aktiv8.io/news/nnmhub3/klondike-gold-reports-additional-montana-creek-royalty-gold-receipts-announces-phase-2-202 2026-08-26 never 0.6 https://aktiv8.io/news/n17sdxpb/haisco-licenses-immunology-asset-to-sentivera-in-deal-worth-more-than-1-5-billion-the-phar 2026-08-26 never 0.6 https://aktiv8.io/news/nfps09f/biotech-stocks-facing-fda-decision-in-september-2026-rttnews 2026-08-26 never 0.6 https://aktiv8.io/news/n1mew32g/imunon-to-host-2026-r-d-day-highlighting-phase-3-ovation-3-trial-and-the-clinical-potentia 2026-08-26 never 0.6 https://aktiv8.io/news/n1ow3rmz/blue-star-gold-announces-phase-2-exploration-drilling-results-at-auma-project-bamako-prosp 2026-08-26 never 0.6 https://aktiv8.io/news/n5rkqrb/caliway-s-cbl-514-combination-therapy-cleared-by-u-s-fda-for-phase-2-trial-pivotal-phase-3 2026-08-26 never 0.6 https://aktiv8.io/news/n1tnmsh6/fda-approves-new-indications-for-ziihera-the-pharma-letter 2026-08-26 never 0.6 https://aktiv8.io/news/n1r8n0mq/stat-fda-approves-new-pancreatic-cancer-drug-expected-to-usher-in-new-era-of-treatment 2026-08-26 never 0.6 https://aktiv8.io/news/n3nejdp/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational-polytherapy-potential-for-az 2026-08-26 never 0.6 https://aktiv8.io/news/n1o0qpvu/centrix-and-university-of-sussex-collaborate-to-drive-data-driven-pharma-development 2026-08-26 never 0.6 https://aktiv8.io/news/nkrdem0/roche-receives-fda-approval-for-companion-diagnostic-tests-to-identify-patients-with-her2- 2026-08-26 never 0.6 https://aktiv8.io/news/n18r6vxf/agenus-announces-updated-nest-phase-2-publication-reporting-deep-pathologic-responses-and- 2026-08-26 never 0.6 https://aktiv8.io/news/n19abyo9/xenon-to-highlight-phase-3-x-tole2-clinical-data-and-rational-polytherapy-potential-for-az 2026-08-26 never 0.6 https://aktiv8.io/news/nkzowrq/radiopharm-theranostics-doses-first-patient-in-second-cohort-of-phase-1-2a-clinical-trial- 2026-08-26 never 0.6 https://aktiv8.io/news/njr7rfp/immuneering-comments-on-today-s-fda-approval-in-second-line-metastatic-pancreatic-cancer-r 2026-08-26 never 0.6 https://aktiv8.io/news/n1ocji7y/monod-bio-licenses-ai-designed-protein-technologies-to-signalchem-biotech-for-custom-disco 2026-08-26 never 0.6 https://aktiv8.io/news/n11cwtnb/bausch-lomb-advances-dual-action-dry-eye-drop-to-phase-3-reports-positive-bl1332-pain-data 2026-08-26 never 0.6 https://aktiv8.io/news/n1fg4qhz/flagship-s-profound-partners-with-gates-foundation-in-35m-preeclampsia-target-discovery-pa 2026-08-26 never 0.6 https://aktiv8.io/news/nas6bo0/revir-therapeutics-receives-fda-rare-pediatric-disease-designation-for-rtx-117-in-charcot- 2026-08-26 never 0.6 https://aktiv8.io/news/ndakv7z/metsera-backers-establish-new-biotech-armed-with-china-licensed-immunology-asset-pharmaceu 2026-08-26 never 0.6 https://aktiv8.io/news/n1oszwla/monod-bio-licenses-ai-designed-protein-technologies-to-signalchem-biotech-for-custom-disco 2026-08-26 never 0.6 https://aktiv8.io/news/n1txb618/viva-biotech-announces-its-2026-interim-results-ai-sparks-new-paradigm-in-drug-r-d-cdmo-co 2026-08-26 never 0.6 https://aktiv8.io/news/n1u7rmko/argenx-just-landed-another-phase-3-win-and-wall-street-may-be-missing-the-bigger-story-aol 2026-08-26 never 0.6 https://aktiv8.io/news/n1epgaw2/jama-dermatology-publishes-skin-specific-outcomes-from-phase-3-valor-trial-of-brepocitinib 2026-08-26 never 0.6 https://aktiv8.io/news/n4fynft/noetik-achieves-first-milestone-in-landmark-gsk-collaboration 2026-08-26 never 0.6 https://aktiv8.io/news/nurz704/ultragenyx-delivers-first-gene-therapy-fda-approval-for-gsdia-streetwise-reports 2026-08-26 never 0.6 https://aktiv8.io/news/n3b8yzm/revmed-receives-early-fda-approval-for-groundbreaking-pancreatic-cancer-drug 2026-08-26 never 0.6 https://aktiv8.io/news/n1nut89p/capricor-s-dmd-therapy-still-alive-merck-moderna-s-cancer-vax-shines-fda-s-future-revealed 2026-08-26 never 0.6 https://aktiv8.io/news/nijcv7b/paradromics-receives-fda-approval-to-expand-bci-access-to-personal-computing-devices-in-co 2026-08-26 never 0.6 https://aktiv8.io/news/n193slf1/nomad-power-solutions-inc-receives-doe-authorization-to-advance-vermont-long-duration-ener 2026-08-26 never 0.6 https://aktiv8.io/news/n1dhknvi/nucleus-and-legacy-partner-to-help-families-decide-if-ivf-is-right-for-them 2026-08-26 never 0.6 https://aktiv8.io/news/n16wamiw/beone-medicines-announces-u-s-fda-approval-for-tevimbra-based-regimen-for-first-line-her2- 2026-08-26 never 0.6 https://aktiv8.io/news/nabjkk8/biohaven-could-get-up-to-795m-in-epilepsy-alliance-with-sk-bio 2026-08-26 never 0.6 https://aktiv8.io/news/n1ufe26f/imunon-to-host-2026-r-d-day-highlighting-phase-3-ovation-3-trial-and-the-clinical-potentia 2026-08-26 never 0.6 https://aktiv8.io/news/n1fe3cv6/summit-therapeutics-smmt-gains-premarket-on-positive-phase-3-t-gurufocus 2026-08-26 never 0.6 https://aktiv8.io/news/n4vcuhf/argenx-just-landed-another-phase-3-win-and-wall-street-may-be-missing-the-bigger-story-the 2026-08-26 never 0.6 https://aktiv8.io/news/n1lle01x/antengene-receives-clinical-trial-approval-in-australia-for-phase-i-attract-study-of-atg-2 2026-08-25 never 0.6 https://aktiv8.io/news/n8fdwq/icg-silver-gold-advances-phase-1-drilling-to-2-525-meters-across-four-targets-at-tuscarora 2026-08-25 never 0.6 https://aktiv8.io/news/n1khe7qv/374water-s-mobile-airscwo-system-completes-phase-3-of-the-st-cloud-mn-mobile-airscwo-deplo 2026-08-25 never 0.6 https://aktiv8.io/news/n1nbnren/linkage-global-s-clickclack-chief-scientist-recognized-for-coma-awakening-research-as-comp 2026-08-25 never 0.6 https://aktiv8.io/news/n19hu5e/polaryx-therapeutics-advances-operational-readiness-for-soteria-phase-2-basket-trial-plyx- 2026-08-25 never 0.6 https://aktiv8.io/news/n1pewkns/b-r-technology-merger-corp-announces-closing-of-exercise-of-ipo-over-allotment-option 2026-08-25 never 0.6 https://aktiv8.io/news/n1i49t99/incannex-announces-first-patient-dosed-in-dreamzz-phase-2-study-of-ihl-42x-ixhl-stock-news 2026-08-25 never 0.6 https://aktiv8.io/news/n10e49ae/fosun-pharma-announces-2026-interim-results 2026-08-25 never 0.6 https://aktiv8.io/news/nifa8j8/cambrex-high-point-acheve-les-inspections-prealables-a-l-autorisation-menees-par-la-fda-la 2026-08-25 never 0.6 https://aktiv8.io/news/n83suyb/roche-eli-lilly-get-fda-nod-for-new-alzheimer-s-blood-test 2026-08-25 never 0.6 https://aktiv8.io/news/n1132c3t/enwave-announces-healthy-snack-launch-of-loovies-llc-a-previously-unnamed-royalty-partner 2026-08-25 never 0.6 https://aktiv8.io/news/n1xjw65e/cellenkos-receives-fda-fast-track-designation-for-ck0803-in-amyotrophic-lateral-sclerosis- 2026-08-25 never 0.6 https://aktiv8.io/news/n36wh3a/nippon-shinyaku-s-lead-drug-candidate-faces-3-month-fda-review-extension-after-agency-acce 2026-08-25 never 0.6 https://aktiv8.io/news/n1gl9cvl/brm424-phase-2-enrollment-complete-with-safety-profile-superior-to-existing-therapies-q4-d 2026-08-25 never 0.6 https://aktiv8.io/news/nw3oha4/capricor-secures-reprieve-as-fda-extends-dmd-cell-therapy-review 2026-08-25 never 0.6 https://aktiv8.io/news/nhcx07h/pretzel-therapeutics-advances-px578-into-phase-2-study-in-individuals-living-with-polg-med 2026-08-25 never 0.6 https://aktiv8.io/news/nevsbh8/caliway-s-cbl-514-combination-therapy-cleared-by-u-s-fda-for-phase-2-trial-pivotal-phase-3 2026-08-25 never 0.6 https://aktiv8.io/news/n1do5rhl/cambrex-high-point-completes-fda-pmda-and-tga-pre-approval-inspections-advancing-commercia 2026-08-25 never 0.6 https://aktiv8.io/news/n17jecho/antengene-receives-clinical-trial-approval-in-australia-for-phase-i-attract-study-of-atg-2 2026-08-25 never 0.6 https://aktiv8.io/news/nxe3bkj/masimo-receives-fda-510-k-clearance-for-root-with-lidco-and-the-masimo-lidco-sensor-to-pro 2026-08-25 never 0.6 https://aktiv8.io/news/nh88f0b/apollo-therapeutics-announces-positive-immunogenicity-data-and-cross-species-activity-from 2026-08-25 never 0.6 https://aktiv8.io/news/nayb91t/fosun-pharma-announces-2026-interim-results 2026-08-25 never 0.6 https://aktiv8.io/news/n1kggsuk/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patien 2026-08-25 never 0.6 https://aktiv8.io/news/n18eqrdm/hanmi-pharm-genentech-ink-2-3b-obesity-drug-licensing-deal-contract-pharma 2026-08-25 never 0.6 https://aktiv8.io/news/nd1fhlg/celea-therapeutics-will-present-phase-3-trial-design-for-idiopathic-pulmonary-fibrosis-and 2026-08-25 never 0.6 https://aktiv8.io/news/n1f03xly/geovax-advances-geo-mva-toward-pivotal-phase-3-study-implementation-tradingview 2026-08-25 never 0.6 https://aktiv8.io/news/n9183f7/allegheny-health-network-and-the-start-center-for-cancer-research-announce-strategic-colla 2026-08-25 never 0.6 https://aktiv8.io/news/n1c98m3d/basking-biosciences-announces-positive-topline-phase-1-data-for-bb-025-the-reversal-agent- 2026-08-25 never 0.6 https://aktiv8.io/news/n16onnau/fda-clinical-hold-for-regenxbio-s-rgx-121-for-mps-the-pharma-letter 2026-08-25 never 0.6 https://aktiv8.io/news/n171anf3/stat-sword-health-to-acquire-headspace-according-to-filing 2026-08-25 never 0.6 https://aktiv8.io/news/ngfoxz6/ivonescimab-plus-chemotherapy-demonstrates-significant-overall-survival-benefit-versus-dur 2026-08-25 never 0.6 https://aktiv8.io/news/n1vmop30/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patien 2026-08-25 never 0.6 https://aktiv8.io/news/n1bouy38/mahzi-therapeutics-announces-fda-rare-pediatric-disease-designation-for-mz-1866-investigat 2026-08-25 never 0.6 https://aktiv8.io/news/nxhsmq2/molecular-partners-reports-h1-2026-financial-results-and-corporate-highlights-dll3-radioth 2026-08-25 never 0.6 https://aktiv8.io/news/nak2dbq/the-lancet-neurology-publishes-data-from-alkermes-positive-vibrance-1-phase-2-study-of-ali 2026-08-25 never 0.6 https://aktiv8.io/news/ndhqvx5/capricor-secures-reprieve-as-fda-extends-dmd-cell-therapy-review 2026-08-25 never 0.6 https://aktiv8.io/news/n1ncg5gg/fda-extends-deramiocel-review-as-capricor-narrows-duchenne-claim-the-pharma-letter 2026-08-25 never 0.6 https://aktiv8.io/news/nvxqw2k/abbott-receives-fda-authorization-for-world-s-first-dual-glucose-ketone-sensing-technology 2026-08-25 never 0.6 https://aktiv8.io/news/n1adhe5h/bausch-lomb-advances-dry-eye-disease-drug-to-phase-3-despite-mid-stage-fail 2026-08-25 never 0.6 https://aktiv8.io/news/nepis1w/merck-and-moderna-s-individualised-mrna-melanoma-vaccine-just-won-a-phase-3-trial-outright 2026-08-25 never 0.6 https://aktiv8.io/news/n18t8si6/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-th 2026-08-25 never 0.6 https://aktiv8.io/news/n11aggnp/cambrex-high-point-completes-fda-pmda-and-tga-pre-approval-inspections-advancing-commercia 2026-08-25 never 0.6 https://aktiv8.io/news/n138cvug/cambrex-high-point-completes-fda-pmda-and-tga-pre-approval-inspections-advancing-commercia 2026-08-25 never 0.6 https://aktiv8.io/news/n1infy8b/cellenkos-receives-fda-fast-track-designation-for-ck0803-in-amyotrophic-lateral-sclerosis- 2026-08-25 never 0.6 https://aktiv8.io/news/n1gzskhr/cambrex-high-point-completa-las-inspecciones-previas-a-la-aprobacion-de-la-fda-la-pmda-y-l 2026-08-25 never 0.6 https://aktiv8.io/news/n4lxxuf/beone-medicines-announces-u-s-fda-approval-for-tevimbra-based-regimen-for-first-line-her2- 2026-08-25 never 0.6 https://aktiv8.io/news/n1rfwk48/cambrex-high-point-schlie-t-die-inspektionen-im-vorfeld-der-zulassung-durch-die-fda-die-pm 2026-08-25 never 0.6 https://aktiv8.io/news/n1vs4bej/spyre-therapeutics-announces-topline-results-from-the-rheumatoid-arthritis-sub-study-of-th 2026-08-25 never 0.6 https://aktiv8.io/news/n1glnw2q/stat-fda-promises-new-ai-guidance-and-what-happened-at-epic-s-ugm 2026-08-25 never 0.6 https://aktiv8.io/news/ne4pfia/masimo-receives-fda-510-k-clearance-for-root-with-lidco-and-the-masimo-lidco-sensor-to-pro 2026-08-25 never 0.6 https://aktiv8.io/news/n1h9l82i/fda-says-theravance-tbph-needs-more-data-on-noh-drug-trial-stock-titan 2026-08-25 never 0.6 https://aktiv8.io/news/n1kb7rwb/merck-and-moderna-announced-on-19-august-2026-that-a-personalised-mrna-cancer-vaccine-had- 2026-08-25 never 0.6 https://aktiv8.io/news/n1ubgqm1/mahzi-therapeutics-announces-fda-rare-pediatric-disease-designation-for-mz-1866-investigat 2026-08-25 never 0.6 https://aktiv8.io/news/n1wgdtk1/dare-bioscience-highlights-commercial-transition-ovaprene-phase-3-progress-and-near-term-g 2026-08-25 never 0.6 https://aktiv8.io/news/n1ju10u5/davita-announces-new-value-based-partnership-with-humana-to-expand-care-for-patients-with- 2026-08-25 never 0.6 https://aktiv8.io/news/n19agprv/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patien 2026-08-25 never 0.6 https://aktiv8.io/news/nam4txr/ivonescimab-plus-chemotherapy-demonstrates-significant-overall-survival-benefit-versus-dur 2026-08-25 never 0.6 https://aktiv8.io/news/n8a00zt/spruce-s-successful-fda-talks-plant-seeds-for-q4-filing-of-ultra-rare-disease-drug 2026-08-24 never 0.6 https://aktiv8.io/news/n1vq1x7q/savara-announces-encore-presentations-of-results-from-the-phase-3-clinical-trial-of-molgra 2026-08-24 never 0.6 https://aktiv8.io/news/n1kbxpb3/tme-pharma-advanced-negotiations-for-nox-a12-licensing-agreement-ideal-investisseur 2026-08-24 never 0.6 https://aktiv8.io/news/n1dc4l67/regenxbio-gene-therapy-refiling-plan-derailed-by-fda-hold-over-spine-mri-findings 2026-08-24 never 0.6 https://aktiv8.io/news/nbplqji/the-lancet-neurology-publishes-data-from-alkermes-positive-vibrance-1-phase-2-study-of-ali 2026-08-24 never 0.6 https://aktiv8.io/news/nezhgrj/savara-announces-encore-presentations-of-results-from-the-phase-3-clinical-trial-of-molgra 2026-08-24 never 0.6 https://aktiv8.io/news/nocm9mc/lexicon-pharmaceuticals-earns-third-10-million-milestone-payment-from-novo-nordisk-followi 2026-08-24 never 0.6 https://aktiv8.io/news/njq5ooo/erasca-granted-fda-fast-track-designation-for-pan-ras-molecular-glue-eras-0015-in-patients 2026-08-24 never 0.6 https://aktiv8.io/news/ni0izex/liminatus-pharma-engages-synex-as-contract-research-organization-to-support-phase-1-2a-cli 2026-08-24 never 0.6 https://aktiv8.io/news/n1txcf6s/ongold-affirms-tpk-drill-program-readiness-reports-exploration-grab-assays-up-to-17-96-g-t 2026-08-24 never 0.6 https://aktiv8.io/news/n45quad/capricor-replimune-reviews-signal-fda-s-return-to-reliability-but-every-application-will-s 2026-08-24 never 0.6 https://aktiv8.io/news/nvew8s/capricor-therapeutics-announces-extension-of-pdufa-target-action-date-as-fda-continues-rev 2026-08-24 never 0.6 https://aktiv8.io/news/n18x4vxl/arrowhead-pharmaceuticals-to-present-new-clinical-data-at-the-european-society-of-cardiolo 2026-08-24 never 0.6 https://aktiv8.io/news/n1m6eg3d/united-therapeutics-corporation-announces-fda-filing-acceptance-of-new-drug-application-fo 2026-08-24 never 0.6 https://aktiv8.io/news/n1vzks9f/regenxbio-s-hunter-syndrome-gene-therapy-hit-by-fda-hold-stymieing-resubmission-plans 2026-08-24 never 0.6 https://aktiv8.io/news/nrv0t7y/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt 2026-08-24 never 0.6 https://aktiv8.io/news/n1ai5kf7/capricor-s-duchenne-therapy-has-new-life-after-fda-grants-3-month-extension 2026-08-24 never 0.6 https://aktiv8.io/news/nbidpfw/quest-diagnostics-to-offer-fda-cleared-roche-ptau217-blood-test-to-assess-alzheimer-s-dise 2026-08-24 never 0.6 https://aktiv8.io/news/n2pogan/roche-receives-fda-clearance-for-elecsys-ptau217-advancing-alzheimer-s-disease-assessment- 2026-08-24 never 0.6 https://aktiv8.io/news/ngrz8xd/reaching-maturity-a-roadmap-for-quality-excellence-amid-regulatory-transformation 2026-08-24 never 0.6 https://aktiv8.io/news/n1lwh9ej/roche-eli-lilly-net-fda-approval-for-first-of-its-kind-alzheimer-s-biomarker-blood-test 2026-08-24 never 0.6 https://aktiv8.io/news/n1dd7f28/3-firms-build-biotech-merger-with-150m-in-private-funding-law360 2026-08-24 never 0.6 https://aktiv8.io/news/nhg9h2c/gc-biopharma-s-hunter-syndrome-treatment-hunterase-receives-drug-approval-in-india-and-tai 2026-08-24 never 0.6 https://aktiv8.io/news/ny1xq5b/brinsupri-brensocatib-approved-by-japan-s-ministry-of-health-labour-and-welfare-for-the-tr 2026-08-24 never 0.6 https://aktiv8.io/news/n17k3e5q/moderna-and-merck-report-positive-phase-3-results-for-personalized-cancer-therapy-mega-doc 2026-08-24 never 0.6 https://aktiv8.io/news/nyk2wv9/labcorp-to-offer-first-fda-cleared-blood-test-to-detect-alzheimer-s-disease-pathology-in-b 2026-08-24 never 0.6 https://aktiv8.io/news/n1mhu1t5/hanmi-pharm-signs-massive-licensing-deal-with-us-biotech-firm-for-obesity-drug-aju-press 2026-08-24 never 0.6 https://aktiv8.io/news/npjkx87/personalized-mrna-cancer-vaccine-clears-phase-3-melanoma-recurrence-cut-by-half-tech-times 2026-08-24 never 0.6 https://aktiv8.io/news/n1j9l6yz/spruce-biosciences-announces-positive-pre-bla-meetings-with-fda-and-confirms-bla-submissio 2026-08-24 never 0.6 https://aktiv8.io/news/nqs50im/3-firms-build-biotech-merger-with-150m-in-private-funding-law360 2026-08-24 never 0.6 https://aktiv8.io/news/n11hci1b/stat-fda-pauses-regenxbio-gene-therapy-trial-again-due-to-safety-concerns 2026-08-24 never 0.6 https://aktiv8.io/news/nbtlw43/stat-fda-digital-health-leader-promises-generative-ai-regulatory-guidance-is-coming 2026-08-24 never 0.6 https://aktiv8.io/news/nti2ziq/vanda-pharmaceuticals-granted-orphan-designation-for-imsidolimab-for-the-treatment-of-gene 2026-08-24 never 0.6 https://aktiv8.io/news/n103ot8k/roche-signs-licensing-deal-for-obesity-treatment-worth-up-to-usd-2-3bn-medwatch-com 2026-08-24 never 0.6 https://aktiv8.io/news/n15eh262/gilead-sciences-gild-fda-approvals-pdufa-dates-drug-alerts-2026-gild-marketbeat-com 2026-08-24 never 0.6 https://aktiv8.io/news/njdrtek/gc-biopharma-s-hunter-syndrome-treatment-hunterase-receives-drug-approval-in-india-and-tai 2026-08-24 never 0.6 https://aktiv8.io/news/n1b1lnij/hanmi-pharm-inks-obesity-license-deal-with-genentech-the-pharma-letter 2026-08-24 never 0.6 https://aktiv8.io/news/n1886rmp/infleqtion-collaboration-with-japan-moonshot-program-achieves-major-milestone-shunkai-neut 2026-08-24 never 0.6 https://aktiv8.io/news/n1p5shtw/insmed-insm-fda-approvals-pdufa-dates-drug-alerts-2026-marketbeat 2026-08-24 never 0.6 https://aktiv8.io/news/n1a5y9d4/precision-biosciences-commences-dosing-in-phase-1-2-function-dmd-study-dtil-stock-news 2026-08-24 never 0.6 https://aktiv8.io/news/n1oo7pu2/zoomcar-and-uber-partner-to-give-travelers-more-ways-to-plan-road-trips 2026-08-24 never 0.6 https://aktiv8.io/news/n1rfnsoy/takeda-pharmaceutical-tak-fda-approvals-pdufa-dates-drug-alerts-2026-tak-marketbeat 2026-08-24 never 0.6 https://aktiv8.io/news/nfq71y1/u-s-fda-grants-orphan-drug-designation-to-gamgertamig-for-the-treatment-of-pemphigus 2026-08-24 never 0.6 https://aktiv8.io/news/npg7awz/spruce-s-successful-fda-talks-plant-seeds-for-q4-filing-of-ultra-rare-disease-drug 2026-08-24 never 0.6 https://aktiv8.io/news/ngs45oy/orum-to-begin-phase-i-trial-of-orm-1153-after-fda-clearance 2026-08-24 never 0.6 https://aktiv8.io/news/n111eyy/biocardia-announces-fda-confirms-helix-transendocardial-delivery-catheter-meeting-minutes- 2026-08-24 never 0.6 https://aktiv8.io/news/n4g5fo7/quest-diagnostics-to-offer-fda-cleared-roche-ptau217-blood-test-to-assess-alzheimer-s-dise 2026-08-24 never 0.6 https://aktiv8.io/news/nhpdrr3/favorable-fda-panel-vote-points-toward-increased-demand-for-peptide-fulfillment-services 2026-08-24 never 0.6 https://aktiv8.io/news/nfk2tj/fda-extends-review-of-capricor-cell-therapy-pain-drug-startup-to-go-public 2026-08-24 never 0.6 https://aktiv8.io/news/n19r1ynv/savara-announces-encore-presentations-of-results-from-the-phase-3-clinical-trial-of-molgra 2026-08-24 never 0.6 https://aktiv8.io/news/n1sqditi/antengene-receives-clinical-trial-approval-in-australia-for-phase-i-attract-study-of-atg-2 2026-08-24 never 0.6 https://aktiv8.io/news/ncyvxj8/labcorp-to-offer-first-fda-cleared-blood-test-to-detect-alzheimer-s-disease-pathology-in-b 2026-08-24 never 0.6 https://aktiv8.io/news/nh88lmk/savara-svra-to-present-phase-3-impala-2-trial-data-highlightin-gurufocus 2026-08-24 never 0.6 https://aktiv8.io/news/n4xj9ge/humacyte-plans-november-2026-supplemental-bla-submission-for-atev-dialysis-access-based-on 2026-08-24 never 0.6 https://aktiv8.io/news/n1vxb19m/erasca-granted-fda-fast-track-designation-for-pan-ras-molecular-glue-eras-0015-in-patients 2026-08-24 never 0.6 https://aktiv8.io/news/n1r0y0h6/moderna-reports-a-cancer-vaccine-breakthrough-consumeraffairs 2026-08-24 never 0.6 https://aktiv8.io/news/n65c2p6/regenxbio-gene-therapy-refiling-plan-derailed-by-fda-hold-over-spine-mri-findings 2026-08-24 never 0.6 https://aktiv8.io/news/n13ez3hz/united-therapeutics-corporation-announces-fda-filing-acceptance-of-new-drug-application-fo 2026-08-24 never 0.6 https://aktiv8.io/news/nuoltrt/tempus-receives-fda-clearance-for-its-ai-product-intended-to-detect-signs-of-pulmonary-hyp 2026-08-24 never 0.6 https://aktiv8.io/news/n1qgzteb/monte-rosa-therapeutics-announces-first-patient-dosed-in-modefire-1-a-phase-2-study-of-mrt 2026-08-24 never 0.6 https://aktiv8.io/news/noh9e4l/veraxa-biotech-and-secarna-pharmaceuticals-achieve-research-milestone-in-antibody-oligonuc 2026-08-24 never 0.6 https://aktiv8.io/news/nvyb474/lebrikizumab-phase-3-data-show-improvements-in-atopic-dermatitis-symptoms-itch-in-children 2026-08-24 never 0.6 https://aktiv8.io/news/n1jrdn5v/3-firms-build-biotech-merger-with-150m-in-private-funding-law360 2026-08-24 never 0.6 https://aktiv8.io/news/nln1o92/avulux-granted-fda-de-novo-authorization-creating-the-first-lens-classification-for-migrai 2026-08-24 never 0.6 https://aktiv8.io/news/njlo7es/merck-and-moderna-s-personalized-cancer-therapy-shows-positive-phase-3-results-morocco-wor 2026-08-24 never 0.6 https://aktiv8.io/news/nrj0f0o/safety-concerns-spur-fda-to-again-halt-testing-of-regenxbio-gene-therapy 2026-08-24 never 0.6 https://aktiv8.io/news/n18758uq/humacyte-confirms-plans-for-atev-supplemental-bla-filing-for-dialysis-access-following-fda 2026-08-24 never 0.6 https://aktiv8.io/news/nw6ncff/roche-receives-fda-clearance-for-elecsys-ptau217-advancing-alzheimer-s-disease-assessment- 2026-08-24 never 0.6 https://aktiv8.io/news/n1emkj5n/anbogen-therapeutics-and-the-university-of-tokyo-enter-collaborative-research-agreement-to 2026-08-23 never 0.6 https://aktiv8.io/news/nyvi12t/moderna-s-mrna-flu-vaccine-approved-by-fda-when-is-it-available-medical-news-today 2026-08-23 never 0.6 https://aktiv8.io/news/no0j2jc/mankind-pharma-expands-diabetes-portfolio-through-exclusive-insulin-licensing-agreement-ma 2026-08-22 never 0.6 https://aktiv8.io/news/n1c98g5z/stephane-bancel-positive-phase-3-results-for-mrna-based-neoantigen-therapy-in-melanoma-onc 2026-08-22 never 0.6 https://aktiv8.io/news/nu80eh6/highest-fda-recall-issued-for-certain-convenience-kits-by-medline 2026-08-22 never 0.6 https://aktiv8.io/news/n8qun5o/ugn-103-nda-filing-for-recurrent-bladder-cancer-might-change-the-case-for-investing-in-uro 2026-08-22 never 0.6 https://aktiv8.io/news/n1qoxi62/ugn-103-nda-filing-for-recurrent-bladder-cancer-might-change-the-case-for-investing-in-uro 2026-08-21 never 0.6 https://aktiv8.io/news/n19yiu5y/ugn-103-nda-filing-for-recurrent-bladder-cancer-might-change-the-case-for-investing-in-uro 2026-08-21 never 0.6 https://aktiv8.io/news/n1dace0n/fda-authorizes-zyn-ultra-nicotine-pouches-following-scientific-review 2026-08-21 never 0.6 https://aktiv8.io/news/ntzm3kg/werewolf-transforms-into-ambros-via-reverse-merger-to-support-phase-3-push-for-rare-diseas 2026-08-21 never 0.6 https://aktiv8.io/news/nm40pt2/mankind-pharma-signs-in-licensing-deal-for-insulin-aspart-and-insulin-degludec-business-st 2026-08-21 never 0.6 https://aktiv8.io/news/n1fh3dzy/implantica-receives-fda-approval-for-refluxstop-opening-the-u-s-market 2026-08-21 never 0.6 https://aktiv8.io/news/n9zhfuo/dizal-to-present-emerging-data-on-zegfrovy-in-non-small-cell-lung-cancer-at-wclc-2026 2026-08-21 never 0.6 https://aktiv8.io/news/n1jrh8ma/dizal-to-present-emerging-data-on-zegfrovy-in-non-small-cell-lung-cancer-at-wclc-2026 2026-08-21 never 0.6 https://aktiv8.io/news/n1hg6y06/novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial-medical-ne 2026-08-21 never 0.6 https://aktiv8.io/news/n1547yqo/abbvie-to-present-new-data-at-wclc-2026-showcasing-innovation-across-lung-cancer-pipeline 2026-08-21 never 0.6 https://aktiv8.io/news/nvuuc9d/werewolf-and-ambros-therapeutics-announce-merger-the-pharma-letter 2026-08-21 never 0.6 https://aktiv8.io/news/nb6jkz8/mankind-pharma-signs-exclusive-in-licensing-deal-for-insulin-analogues-in-india-surprise-f 2026-08-21 never 0.6 https://aktiv8.io/news/n1jo47x9/implantica-receives-fda-approval-for-refluxstop-opening-the-u-s-market 2026-08-21 never 0.6 https://aktiv8.io/news/nizxm5p/chronic-pain-biotech-co-founded-by-vivek-ramaswamy-joins-reverse-merger-train 2026-08-21 never 0.6 https://aktiv8.io/news/nhsmk1i/lawmakers-urge-fda-to-enact-new-china-policies-after-3-gene-therapy-deaths-biospace 2026-08-21 never 0.6 https://aktiv8.io/news/n1vdlank/moderna-s-ai-designed-mrna-melanoma-vaccine-succeeds-in-phase-3-trial-hypefresh-com 2026-08-21 never 0.6 https://aktiv8.io/news/n1c4wmy1/arkg-etf-price-forecast-arkg-47-hits-all-time-high-on-10-32-session-after-moderna-phase-3- 2026-08-21 never 0.6 https://aktiv8.io/news/nr0wuo8/werewolf-transforms-into-ambros-via-reverse-merger-to-support-phase-3-push-for-rare-diseas 2026-08-21 never 0.6 https://aktiv8.io/news/nisgfh9/immuneonco-biopharmaceuticals-shanghai-receives-fda-approval-for-ind-application-of-imm030 2026-08-21 never 0.6 https://aktiv8.io/news/n1943fwv/belite-bio-sets-four-talks-at-two-medical-meetings-including-phase-3-data-stock-titan 2026-08-21 never 0.6 https://aktiv8.io/news/n1xdwv17/lupin-signs-exclusive-licensing-agreement-for-yuvezzi-in-europe-express-pharma 2026-08-21 never 0.6 https://aktiv8.io/news/npmv5gq/tokyo-s-taiho-and-cullinan-announce-positive-phase-3-lung-cancer-results-geneonline-com 2026-08-21 never 0.6 https://aktiv8.io/news/nnywlk9/moderna-merck-near-first-personalized-mrna-cancer-vaccine-after-phase-3-win-geneonline-com 2026-08-21 never 0.6 https://aktiv8.io/news/n1diocz7/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-nda-accepted-by-nmpa-poised-to- 2026-08-21 never 0.6 https://aktiv8.io/news/ni1cb80/abbvie-to-present-new-data-at-wclc-2026-showcasing-innovation-across-lung-cancer-pipeline 2026-08-21 never 0.6 https://aktiv8.io/news/nwlnxc0/werewolf-therapeutics-and-ambros-therapeutics-announce-150-million-financing-and-merger-to 2026-08-21 never 0.6 https://aktiv8.io/news/n11e3x5k/milestone-pharmaceuticals-enrolls-first-patient-in-phase-3-revera-301-trial-of-etripamil-f 2026-08-21 never 0.6 https://aktiv8.io/news/nusyf7u/before-its-recent-phase-3-lsd-win-definium-modeled-up-to-70-000-a-year-for-a-therapy-that- 2026-08-21 never 0.6 https://aktiv8.io/news/nvthvci/lawmakers-urge-fda-to-enact-new-china-policies-after-3-gene-therapy-trial-deaths 2026-08-21 never 0.6 https://aktiv8.io/news/ndf2vpo/milestone-pharmaceuticals-initiates-pivotal-phase-3-trial-of-etripamil-nasal-spray-for-sel 2026-08-21 never 0.6 https://aktiv8.io/news/nd9rek4/werewolf-therapeutics-and-ambros-therapeutics-announce-merger-agreement-and-concurrent-ove 2026-08-21 never 0.6 https://aktiv8.io/news/nyt4up9/gossamer-bio-announces-up-to-250-million-structured-private-placement-including-150-millio 2026-08-21 never 0.6 https://aktiv8.io/news/n1ua8yt0/interpath-001-trial-of-mrna-based-individualized-neoantigen-therapy-meets-primary-and-key- 2026-08-21 never 0.6 https://aktiv8.io/news/nu4m2v0/pharmala-biotech-provides-corporate-update-u-s-patent-granted-covering-novel-enantioselect 2026-08-21 never 0.6 https://aktiv8.io/news/n6fa215/techlusion-named-an-openai-select-partner 2026-08-21 never 0.6 https://aktiv8.io/news/n11surw8/hyperfine-announces-fda-clearance-of-the-next-optive-ai-software-further-enhancing-image-q 2026-08-20 never 0.6 https://aktiv8.io/news/n227v48/neoimmunetech-soars-on-first-post-listing-license-out-with-us-partner-chosunbiz-chosunbiz 2026-08-20 never 0.6 https://aktiv8.io/news/nvrf14i/stat-capricor-therapeutics-duchenne-treatment-is-heading-for-an-fda-rejection 2026-08-20 never 0.6 https://aktiv8.io/news/n18gmiqk/adaptin-bio-announces-opening-of-enrollment-in-a-phase-1-clinical-trial-evaluating-treatme 2026-08-20 never 0.6 https://aktiv8.io/news/n1k6xaa4/boehringer-places-phase-1-study-of-investigational-drug-on-hold-to-examine-safety-event 2026-08-20 never 0.6 https://aktiv8.io/news/n1rqtkhp/lilly-pens-deal-with-gateway-labs-resident-amplitude-for-rna-vaccine-platform-for-infectio 2026-08-20 never 0.6 https://aktiv8.io/news/n3c7wd4/expert-reaction-moderna-announce-results-of-phase-3-trial-of-personalized-mrna-cancer-vacc 2026-08-20 never 0.6 https://aktiv8.io/news/nlalsma/amylyx-raises-500-million-to-advance-avexitide-after-positive-phase-3-pbh-results-biopharm 2026-08-20 never 0.6 https://aktiv8.io/news/n1rzyt9w/ac-immune-announces-positive-preliminary-phase-1-data-for-nlrp3-inhibitor-aci-19764 2026-08-20 never 0.6 https://aktiv8.io/news/n13qlja3/moderna-merck-breakthrough-cancer-vaccine-shows-promise-in-clinical-trial-for-melanoma-tre 2026-08-20 never 0.6 https://aktiv8.io/news/n5kzc4y/evolved-by-nature-s-peptide-platform-used-in-fda-cleared-prescription-therapy-for-the-mana 2026-08-20 never 0.6 https://aktiv8.io/news/np7yqdt/evolved-by-nature-s-peptide-platform-used-in-fda-cleared-prescription-therapy-for-the-mana 2026-08-20 never 0.6 https://aktiv8.io/news/n14e7sb7/stat-how-a-trump-loyalist-got-the-fda-nomination 2026-08-20 never 0.6 https://aktiv8.io/news/nuk4fz8/stat-fda-approves-ultragenyx-gene-therapy 2026-08-20 never 0.6 https://aktiv8.io/news/n16hec5c/ultragenyx-after-setbacks-nabs-first-gene-therapy-approval 2026-08-20 never 0.6 https://aktiv8.io/news/n2z2ok7/chutes-ladders-neumora-shuffles-leadership-ahead-of-ind 2026-08-20 never 0.6 https://aktiv8.io/news/n19rjk7y/keenova-advances-podiatry-pipeline-with-first-patient-dosed-in-phase-3-trial-of-xiaflex-co 2026-08-20 never 0.6 https://aktiv8.io/news/n16fvqjt/uk-mhra-grants-approval-for-scancell-s-phase-iii-study-of-iscib1 2026-08-20 never 0.6 https://aktiv8.io/news/n39sdh4/merck-s-moderna-partnered-vaccine-success-clears-view-of-post-keytruda-future 2026-08-20 never 0.6 https://aktiv8.io/news/n119x7bw/creative-medical-technology-holdings-successfully-completes-enrollment-and-treatment-acros 2026-08-20 never 0.6 https://aktiv8.io/news/ne7d43w/merck-moderna-report-positive-phase-3-melanoma-results-for-keytruda-combination-roi-nj 2026-08-20 never 0.6 https://aktiv8.io/news/n1mlkbi5/h-c-wainwright-reiterates-urogen-pharma-stock-rating-on-nda-filing-investing-com 2026-08-20 never 0.6 https://aktiv8.io/news/n17xzg4n/urogen-pharma-inks-licensing-deal-with-intragel-therapeutics-the-pharma-letter 2026-08-20 never 0.6 https://aktiv8.io/news/n10ntwsa/mankind-licenses-insulin-degludec-and-aspart-combo-from-china-s-chenan-bio-pharma-economic 2026-08-20 never 0.6 https://aktiv8.io/news/n3dnns5/stoke-shoes-names-caleb-pressley-as-brand-partner 2026-08-20 never 0.6 https://aktiv8.io/news/nd66mku/mankind-pharma-licenses-two-chinese-insulin-analogues-for-india-the-pharma-letter 2026-08-20 never 0.6 https://aktiv8.io/news/n1gaok5i/blue-star-gold-announces-phase-2-exploration-drilling-results-at-nutaaq-returning-8-0-metr 2026-08-20 never 0.6 https://aktiv8.io/news/na2hal9/iecure-to-present-clinical-data-from-ongoing-otc-hope-trial-of-ecur-506-in-neonatal-onset- 2026-08-20 never 0.6 https://aktiv8.io/news/n160ds35/nuvation-bio-granted-fda-fast-track-designation-for-safusidenib-for-treatment-of-idh1-muta 2026-08-20 never 0.6 https://aktiv8.io/news/nowf236/alzamend-neuro-s-phase-1-2a-lithium-neuroimaging-data-accepted-for-poster-presentation-at- 2026-08-20 never 0.6 https://aktiv8.io/news/n1cwqkf1/rein-therapeutics-receives-u-s-fda-fast-track-designation-for-lti-03-in-idiopathic-pulmona 2026-08-20 never 0.6 https://aktiv8.io/news/n1coby9/keenova-advances-podiatry-pipeline-with-first-patient-dosed-in-phase-3-trial-of-xiaflex-co 2026-08-20 never 0.6 https://aktiv8.io/news/nhsaj4s/selkirk-copper-reports-additional-results-from-the-phase-2-drill-program-including-high-gr 2026-08-20 never 0.6 https://aktiv8.io/news/n1l18vk9/ac-immune-announces-positive-preliminary-phase-1-data-for-nlrp3-inhibitor-aci-19764-aciu-s 2026-08-20 never 0.6 https://aktiv8.io/news/n1pp8jbl/radiopharm-theranostics-receives-positive-recommendation-from-data-safety-and-monitoring-c 2026-08-20 never 0.6 https://aktiv8.io/news/ncoazhj/urogen-pharma-enters-option-and-investment-deal-with-intragel-therapeutics-kalkine-media 2026-08-20 never 0.6 https://aktiv8.io/news/nh3im3k/regeneron-wins-fda-approval-to-challenge-ipsen-for-rare-bone-disease-market 2026-08-20 never 0.6 https://aktiv8.io/news/n1ql1cvw/ultragenyx-bags-first-gene-therapy-approval-as-previously-rejected-sanfilippo-asset-awaits 2026-08-20 never 0.6 https://aktiv8.io/news/n12q7il2/nuvation-bio-granted-fda-fast-track-designation-for-safusidenib-for-treatment-of-idh1-muta 2026-08-20 never 0.6 https://aktiv8.io/news/nfaxd7q/alzamend-neuro-s-phase-1-2a-lithium-neuroimaging-data-accepted-for-poster-presentation-at- 2026-08-20 never 0.6 https://aktiv8.io/news/n1prjerg/intragel-therapeutics-and-urogen-pharma-sign-strategic-collaboration-and-investment-agreem 2026-08-20 never 0.6 https://aktiv8.io/news/n1djssds/mankind-pharma-inks-in-licensing-pact-with-china-s-chongqing-chenan-biopharmaceutical-the- 2026-08-20 never 0.6 https://aktiv8.io/news/n1jziyq1/mankind-pharma-inks-in-licensing-pact-with-china-s-chongqing-chenan-biopharmaceutical-the- 2026-08-20 never 0.6 https://aktiv8.io/news/n5gn2we/implantica-receives-fda-approval-for-refluxstop-opening-the-u-s-market 2026-08-20 never 0.6 https://aktiv8.io/news/n1lq1q29/implantica-receives-fda-approval-for-refluxstop-opening-the-u-s-market 2026-08-20 never 0.6 https://aktiv8.io/news/n1yey007/fda-clearance-of-c2n-diagnostics-precivityad2-blood-test-advances-precision-medicine-for-a 2026-08-20 never 0.6